Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
SEATTLE, Nov. 23, 2016 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 1:00 pm EST at the Lotte New York Palace Hotel.
A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events.’ An audio reply of the webcast will be available following the live webcast.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
[email protected]
